Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). [(FDA OOPD)]
Status | Recruiting |
Enrollment | 24 |
Est. completion date | July 2028 |
Est. primary completion date | October 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects must be at least 18 years of age at the time of signing the Informed Consent Form (ICF); must voluntarily sign an ICF; and be able to meet all study requirements - Morphologically confirmed diagnosis of AML or MDS in accordance with World Health Organization (WHO) diagnostic criteria - Subjects with relapsed/refractory AML who are refractory or relapsed to all conventional therapy and do not have any FDA approved or standard therapeutic options & subjects with intermediated/high/very high IPSS-R MDS who are refractory or relapsed to at least 4 cycles of hypomethylating agent based therapy (azacitidine / decitabine based) OR patients with rapid progression of disease regardless of number of cycles of therapy - WBC must be <25,000 and may be reduced with hydroxyurea to reach this goal prior to study start - At least 3 months from Allogenic stem cell transportation and no clinical sign of active graft vs host disease (GVHD) - A post-consent bone marrow biopsy must be performed and tissue collected for correlative analysis for entrance to this trial. Correlative sample collection will not be optional on this study - Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 - Recovery to = Grade 1 or baseline for any toxicities considered to be due to prior systemic treatments, excluding alopecia - Must have adequate hepatic and renal function as follows: ALT (SGPT) and/or AST (SGOT) = 3x upper limit of normal (ULN) or = 5x ULN if considered to be leukemia related; Direct bilirubin = 1.5 x ULN or = 3x ULN (in patients with know Gilberts syndrome or if considered to be leukemia related) - Serum creatinine clearance = 60 mL/min/1.73 m2 either measured or calculated using standard Cockroft-Gault formula Exclusion Criteria: - Acute Promyelocytic Leukemia - Low or very low risk MDS by IPSS-R after failure/progression of first line therapy with hypomethylating agents - Active, uncontrolled infection. Patients with infection under active treatment and controlled with antibiotics are eligible. Use of prophylactic anti-microbials per institutional standards is allowed. - Active documented central nervous system (CNS) leukemia. Patients with a known history of CNS leukemia will be eligible if they have at least two most recent consecutive LPs showing clearance of CNS disease and no active/progressive symptoms thought to be related to the CNS disease. - Concurrent treatment with a non-permitted concomitant medication (as noted in protocol appendix) - Concurrent anticancer treatment, major surgery, or the use of any investigational drug within 14 days before the start of trial treatment - Other malignancy currently being treated or likely to need treatment in next 6 months with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ, surgically removed malignancies or malignancies definitively treated with chemotherapy, XRT and/or surgery with no evidence of active malignancy or not anticipated to need treatment in next 6 months or malignancies on maintenance therapy (e.g. tamoxifen for breast cancer) will be allowed after discussion and approval by both MPIs - Pregnant or breastfeeding females - Known current alcohol or drug abuse - Clinically significant cardiovascular disease within the past 6 months (e.g. percutaneous intervention, coronary artery bypass graft, documented NYHA class III/IV cardiac heart failure, unstable angina or MI, poorly controlled atrial or ventricular arrhythmia) as determined by the investigator - Any psychiatric condition that would prohibit the understanding or rendering of informed consent - Legal incapacity or limited legal capacity to sign consent and/or participate in the trial - Any condition deemed by the investigator to make the patient a poor candidate for clinical trial and/or treatment with investigational agents. - Previous exposure to the investigational agent (danvatirsen) or to other STAT3 inhibitors |
Country | Name | City | State |
---|---|---|---|
United States | Montefiore Medical Center | Bronx | New York |
United States | M.D. Anderson Cancer Center, Department of Leukemia | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Montefiore Medical Center | Flamingo Therapeutics NV, M.D. Anderson Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response to Therapy as determined by Overall Response Rate | Overall Response Rate (ORR) will be used to assess clinical activity in AML and MDS participants. ORR will be measured as the percentage of participants demonstrating an objective overall response based upon a composite of remission related measures for AML and MDS participants as defined below.
For AML participants, ORR will be defined as any confirmed Complete Remission (CR) + Complete Remission with Incomplete hematologic recovery (CRi) + Partial Remission (PR). or, AML = CR + CRi + PR For MDS participants, ORR will be defined as any confirmed Complete Remission (CR) + Complete Remission with Partial Hematologic Recovery (CRh) + Hematologic Response (HR). or, MDS = CR + CRh + HR Higher percentage is indicative of increased clinical activity of the danvatirsen monotherapy and danvatirsen + venetoclax combination therapies. |
From 21 days after initiation of study treatment to within 14 days following treatment discontinuation; up to 14 weeks total | |
Secondary | Duration of Response | Duration of response will be measured by the number of days from the date of initial response (CRi or better) to the date of first documented disease progression/relapse or death, whichever occurs first. In the event that neither disease progression/relapse or death is documented prior to study termination, analysis cutoff, or the start of confounding anticancer therapy, this endpoint will be censored at the date of last tumor assessment date. An increased duration of response is indicative of how long a patient will respond to treatment without tumor growth or metastasis | Up to 3 years after discontinuation of study treatment; up to 3.5 years total | |
Secondary | Event-free survival | Event-free survival (EFS) will be measured as the number of days from the date of treatment initiation to the date of documented treatment failure, relapse from complete remission, or death from any cause, whichever occurs first. In the event that none of the above are documented prior to study termination, analysis cutoff, or the start of confounding anticancer therapy, this endpoint will be censored at the date of last tumor assessment date | Up to 3 years after discontinuation of study treatment; up to 3.5 years total | |
Secondary | Overall Survival | Overall Survival (OS) will be measured as the number of days from the date of treatment initiation until the date of death | Up to 3 years after discontinuation of study treatment; up to 3.5 years total | |
Secondary | 30 Day All-cause mortality | Number of participant deaths by all causes | 30 days after initiation of study treatment | |
Secondary | 60 Day All-cause Mortality | Number of participant deaths by all causes | 60 days after initiation of study treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |